Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor therapies, FVIII-based immune tolerance induction (ITI) is still the only effective means to inhibitor eradication. With the recently introduced Atlanta protocol, emicizumab prophylaxis is given in combination with 50-100 IU/kg FVIII three times a week. […]
The previous edition of this resource has also been translated into the following languages, with permission from the WFH, by NMOs: Farsi, Setswana This patient handbook contains basic information about prophylaxis, the regular infusion of clotting factor concentrates in order to prevent bleeding. Prophylaxis is the goal of treatment for people with severe hemophilia, allowing […]
The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis targets and outcomes. In this session from the WFH 2020 Virtual Summit, Johnny Mahlangu, Victor Blanchette, Robert Klamroth and Emna Gouider redefine prophylaxis in the modern era by revisiting its definition, presenting data to support […]
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Alok Srivastava, Steven Pipe, Manuel Carcao, Margaret Ragni and Johnny Mahlangu present and discuss updates to the WFH Guidelines for the Management of Hemophilia. Discussion topics include hemostatic agents, prophylaxis, inhibitors, and treatment of specific hemorrhages. Click below to access more on-demand Virtual Summit […]
Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of life for both the person with hemophilia and their family.
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 在宅療法の利用は、医療制度における経済的負担を軽減し、血友病患者とその家族双方の生活の質を向上させます。
Helps identify effective treatment strategies for hemophilia. Topics include delivery of treatment, on-demand treatment, prophylaxis, immune tolerance, and factor assays.